Jazz Pharmaceuticals JAZZ Federal
Federal at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredFederalIncomeTaxExpenseBenefit.
The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's federal.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's federal?
- Jazz Pharmaceuticals (JAZZ) reported federal of -$2.46M in Q4 2025.
- How has Jazz Pharmaceuticals's federal changed year-over-year?
- Jazz Pharmaceuticals's federal increased by 51.0% year-over-year, from -$5.01M to -$2.46M.
- What is the long-term trend for Jazz Pharmaceuticals's federal?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's federal has grown at a 16.2% compound annual growth rate (CAGR), from -$5.39M to -$9.82M.
- What does federal mean?
- The non-cash federal tax impact caused by timing differences between accounting and tax rules.
- How do you interpret federal?
- Large deferred tax benefits often signal future tax savings, while large expenses indicate future tax liabilities.
- How does federal compare across companies?
- Standard accounting disclosure; reflects the company's long-term tax strategy and asset depreciation schedules.